Integrated Pharmaceutical Care on Patients with Coronary Heart Diseaseafter First Percutaneous Coronary Intervention / 中国药学杂志

ABSTRACT

OBJECTIVE: To explore the effect of integrated pharmaceutical intervention on medication compliance, risk factors control, and 6 months and 2 years prognosis in patients with coronary artery disease(CAD) after first percutaneous coronary intervention (PCI) in china. METHODS: 200 cases of patients diagnosed with CAD and underwent PCI successfully firstly in Zhoupu hospital during January 2015 to December were enrolled. The control group was given routine treatment and nursing care; pharmacist intervention group, on this basis, was given pharmaceutical intervention by pharmacists, including optimizing medication program, formulating pharmaceutical care plan, medication education, health education and regular pharmacists outpatient follow-up. The two groups were followed up for two years. Comparison of the Readmission(Readm) rate, incidence rate of major adverse cardiac events (MACEs), Readm expenses, awareness rate of commonly used two-grade preventive drugs for CAD, medication compliance and emotion management after 6 months and two years in the two groups. The control of risk factors in the two groups after 2 years were compared. RESULTS: After six months, the Readm rate, the incidence of MACEs and Readm expenses in pharmacist intervention group were lower than those in the control group, and the medication compliance was slightly higher than the control group (94.9% vs 87.4%); two years later, the standard rate of risk factors in pharmacist intervention group was significantly better than the control group(smoking3.1% vs. 12.6%, P=0.012; blood glucose standard rate79.6% vs. 62.1%, P=0.007; blood pressure standard rate74.5% vs. 53.7%, P=0.003; blood lipid standard rate84.7% vs. 57.9%, P<0.001); and the Readm rate, the incidence of MACEs and the cost of Readm were significantly lower than those of the control group after six months and two years. CONCLUSION: Pharmacists′ active pharmaceutical intervention on patients after PCI can effectively improve the medication compliance of the patients, reduce the postoperative risk factors and the incidence of MACEs, reduce medical expenses, improve the clinical prognosis, which were more significant when the follow-up time was longer.